RecruitingObesity With DiabetesOverweight With Diabetes
Efficacy and Safety of Ribupatide Administered Once Weekly in Participants Living With Obesity or Overweight and Diabetes
Eligible age
18+ yrs
Accepts
All genders
Locations
23 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
The primary objective of this study is to demonstrate that ribupatide (KAI-9531) subcutaneous (SC) injection once weekly is superior to placebo on: * Percent change in body weight * Change in hemoglobin A1c (HbA1c)
Sponsor: Kailera
Where it's recruiting
Source: ClinicalTrials.gov · NCT07284901 · last updated 2026-07-15